“…[1,2] Although TIVAPS are generally associated with a lower long-term risk of infection compared to Hickman-type central venous catheters, [3,4] complications during their placement and long-term use are still a matter of concern. These complications, including infection, catheter fracture, thrombosis and extravasation [5,6,7], may necessitate device replacement, resulting in additional patient stress and treatment delays. Cancer patients have an intrinsically high risk of venous thrombosis, related to both the disease process itself and certain cancer treatments, [8] this risk being further increased by placement of a catheter or TIVAPS.…”